Volume | 0 |
|
|||||
News | - | ||||||
Day High | Low High |
||||||
Day Low |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Equillium Inc | EQ | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
1.81 |
Trades | Volume | Avg Volume | 52 Week Range |
---|---|---|---|
0 | 0 | - | 0.45 - 3.25 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
- | 0 | $ 1.81 | USD |
Equillium Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
63.57M | 35.12M | - | 36.08M | -13.34M | -0.38 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Equillium News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical EQ Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 1.72 | 1.85 | 1.58 | 1.73 | 95,799 | 0.09 | 5.23% |
1 Month | 2.27 | 2.43 | 1.58 | 1.97 | 124,136 | -0.46 | -20.26% |
3 Months | 0.83 | 3.25 | 0.80 | 1.99 | 393,004 | 0.98 | 118.07% |
6 Months | 0.5407 | 3.25 | 0.45 | 1.59 | 258,825 | 1.27 | 234.75% |
1 Year | 0.62 | 3.25 | 0.45 | 1.26 | 207,046 | 1.19 | 191.94% |
3 Years | 6.21 | 7.75 | 0.45 | 2.27 | 140,223 | -4.40 | -70.85% |
5 Years | 5.37 | 30.20 | 0.45 | 14.64 | 410,627 | -3.56 | -66.29% |
Equillium Description
Equillium Inc is a biotechnology developing therapies to treat autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph 2 ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease. |